1. Medtech Insight
  2. >>Device Area
  3. >>Orthopedics

AAOS Roundup: Robotic Ortho Surgery Continues To Gain Traction, Led By Stryker's MAKO

 
• By Marion Webb
  
Generate a summary of this article
Listen to this article
Beta

Stryker is enjoying strong demand for its MAKO robotic surgery platform with plans to increase system placements and procedure volumes while working on a next-gen system that would enhance ease-of-use for surgeons and improve accuracy. The company also has plans to expand into other areas of focus, according to analyst reports from this year's AAOS annual meeting in New Orleans. Meanwhile, Smith & Nephew and Zimmer Biomet are trying to set themselves apart with their robotic technologies.

Human joints, knee and elbow joint, ankle joint and wrist. Medical orthopedic vector set. Anatomy human orthopedic illustration of leg and hand

The robotic movement continues to gain traction with orthopedic surgeons. To further cement their bond with surgeons, the major developers of robotic systems for large joints led by Stryker Corp., as well as Smith & Nephew PLC and Zimmer Biomet Holdings Inc., are presenting their latest news on the sales and marketing front, next-gen applications and clinical study findings at this year's Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS 2018), held March 3-10 in New Orleans. Also see "Latest Mako Tech Fleshes Out Stryker's Robotic Joint Replacement Line But Cost Critics Still There" - Medtech Insight, 20 March, 2017.

After Stryker's big fanfare introduction of the MAKO total knee replacement system last March at AAOS 2017 in San Diego,...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Orthopedics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     
    • By Natasha Barrow

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     
    • By Natasha Barrow

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     
    • By Natasha Barrow

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.